F. Hoffmann-La Roche AG


About Roche

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the twelfth consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2020 employed more than 100,000 people worldwide. In 2020, Roche invested CHF 12.2 billion in R&D and posted sales of CHF 58.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
For more information, please visit www.roche.com.

Roche retains sole responsibility for content © 2021 F. Hoffmann-La Roche AG. All trademarks used or mentioned in this release are protected by law.

1 December 2019 - 30 November 2020

Region: Global
Subject/journal group: All

The table to the right includes counts of all research outputs for F. Hoffmann-La Roche AG published between 1 December 2019 - 30 November 2020 which are tracked by the Nature Index.

Hover over the donut graph to view the FC output for each subject. Below, the same research outputs are grouped by subject. Click on the subject to drill-down into a list of articles organized by journal, and then by title.

Note: Articles may be assigned to more than one subject area.

Count Share
146 58.80

Outputs by subject (Share)

Subject Count Share
Life Sciences 118 41.64
1 0.17
1 0.59
8 3.56
4 1.83
2 0.50
2 0.11
1 0.25
2 0.96
2 1.10
1 1
5 0.31
4 1.22
2 2
3 1.48
3 0.40
10 3.78
2 0.07
2 0.24
17 5.96
muscat detects subpopulation-specific state transitions from multi-sample multi-condition single-cell transcriptomics data
Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07)
Characterization of the pathoimmunology of necrotizing enterocolitis reveals novel therapeutic opportunities
Integrated digital pathology and transcriptome analysis identifies molecular mediators of T-cell exclusion in ovarian cancer
Functional characterization of variants identified by targeted exome-sequencing of 131,668 cancer patients
Format chain exchange (FORCE) for high-throughput generation of bispecific antibodies in combinatorial binder-format matrices
Integrated genomic analysis reveals mutated ELF3 as a potential gallbladder cancer vaccine candidate
In vitro Cas9-assisted editing of modular polyketide synthase genes to produce desired natural product derivatives
Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody
A phenome-wide association and Mendelian Randomisation study of polygenic risk for depression in UK Biobank
Proteogenomics analysis unveils a TFG-RET gene fusion and druggable targets in papillary thyroid carcinomas
Escape mutations circumvent a tradeoff between resistance to a beta-lactam and resistance to a beta-lactamase inhibitor
Lgr5+ telocytes are a signaling source at the intestinal villus tip
Increased circulating levels of Factor H-Related Protein 4 are strongly associated with age-related macular degeneration
Chaperone mediated detection of small molecule target binding in cells
YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation
Transforming Growth Factor-beta signaling in αβ thymocytes promotes negative selection
1 0.48
5 1.05
1 0.09
2 1.56
1 0.92
1 0.11
1 0.08
14 6.64
3 1.93
3 0.77
4 1.06
10 1.42
Chemistry 34 19.67
Physical Sciences 2 0.74
Earth & Environmental Sciences 1 0.50

Highlight of the month

Making the most of single-cell sequencing

© Lucas Ninno/Moment/Getty Images

© Lucas Ninno/Moment/Getty Images

A new method for analysing single-cell RNA sequencing datasets allows researchers to measure changes in biological state across subpopulations of cells in different individuals and under multiple experimental conditions.

Scientists from Roche and elsewhere developed the platform using a simulation framework that mimics various characteristics of single-cell RNA sequencing data, including sample-to-sample variability.

The researchers adapted their models to analyse various subpopulation-specific or condition-specific changes in cell state. They then looked for concordances between the simulations and real-world data.

As a proof of principle, they considered sequencing information from mouse brain cells treated with an inflammation-inducing drug. They were able to identify genes and pathways affected by the treatment both in neuronal and non-neuronal cells.

Known as muscat (short for multi-sample multi-group scRNA-seq analysis tools), the technique should empower scientists to make the most of single-cell gene-expression assays, which are a powerful tool for studying cellular heterogeneity and hierarchies.

Supported content

  1. Nature Communications 11, 6077 (2020). doi: 10.1038/s41467-020-19894-4

View the article on the Nature Index

See more research highlights from F. Hoffmann-La Roche AG

More research highlights from F. Hoffmann-La Roche AG

1 December 2019 - 30 November 2020

International vs. domestic collaboration by Share

  • 8.68% Domestic
  • 91.32% International

Note: Hover over the graph to view the percentage of collaboration.

Note: Collaboration is determined by the fractional count (Share), which is listed in parentheses.

Return to institution outputs